This phenomenon is especially notable in cancer varieties where there are potent targeted therapies for key growth pathways, such as AR‐driven prostate cancer, epidermal growth factor receptor (EGFR)‐mutant lung cancer, and BRAF‐mutant melanoma.4 Here, EGFR is linked to prostate cancer.